245 related articles for article (PubMed ID: 24013748)
1. Immunotherapy at large: the road to personalized cancer vaccines.
Vonderheide RH; Nathanson KL
Nat Med; 2013 Sep; 19(9):1098-100. PubMed ID: 24013748
[No Abstract] [Full Text] [Related]
2. Immunotherapy for melanoma.
Komenaka I; Hoerig H; Kaufman HL
Clin Dermatol; 2004; 22(3):251-65. PubMed ID: 15262312
[TBL] [Abstract][Full Text] [Related]
3. Researchers push for personalized tumour vaccines.
Ledford H
Nature; 2016 Apr; 532(7600):425. PubMed ID: 27121818
[No Abstract] [Full Text] [Related]
4. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
5. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Sahin U; Derhovanessian E; Miller M; Kloke BP; Simon P; Löwer M; Bukur V; Tadmor AD; Luxemburger U; Schrörs B; Omokoko T; Vormehr M; Albrecht C; Paruzynski A; Kuhn AN; Buck J; Heesch S; Schreeb KH; Müller F; Ortseifer I; Vogler I; Godehardt E; Attig S; Rae R; Breitkreuz A; Tolliver C; Suchan M; Martic G; Hohberger A; Sorn P; Diekmann J; Ciesla J; Waksmann O; Brück AK; Witt M; Zillgen M; Rothermel A; Kasemann B; Langer D; Bolte S; Diken M; Kreiter S; Nemecek R; Gebhardt C; Grabbe S; Höller C; Utikal J; Huber C; Loquai C; Türeci Ö
Nature; 2017 Jul; 547(7662):222-226. PubMed ID: 28678784
[TBL] [Abstract][Full Text] [Related]
6. The benefits of immunotherapy combinations.
Schmidt C
Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
[No Abstract] [Full Text] [Related]
7. Cancer neoantigen: Boosting immunotherapy.
Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
[TBL] [Abstract][Full Text] [Related]
8. Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.
Grenier JM; Yeung ST; Khanna KM
Front Immunol; 2018; 9():610. PubMed ID: 29623082
[TBL] [Abstract][Full Text] [Related]
9. Making It Personal: Neoantigen Vaccines in Metastatic Melanoma.
Hellmann MD; Snyder A
Immunity; 2017 Aug; 47(2):221-223. PubMed ID: 28813655
[TBL] [Abstract][Full Text] [Related]
10. The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy.
Cannon MJ; Block MS; Morehead LC; Knutson KL
Immunotherapy; 2019 Feb; 11(2):75-79. PubMed ID: 30730268
[No Abstract] [Full Text] [Related]
11. Cancer vaccines: Material breach.
Dolgin E
Nature; 2013 Dec; 504(7480):S16-7. PubMed ID: 24352360
[No Abstract] [Full Text] [Related]
12. Calling cancer's bluff with neoantigen vaccines.
DeWeerdt S
Nature; 2017 Dec; 552(7685):S76-S77. PubMed ID: 29293229
[No Abstract] [Full Text] [Related]
13. Mathematical model of a personalized neoantigen cancer vaccine and the human immune system.
Rodriguez Messan M; Yogurtcu ON; McGill JR; Nukala U; Sauna ZE; Yang H
PLoS Comput Biol; 2021 Sep; 17(9):e1009318. PubMed ID: 34559809
[TBL] [Abstract][Full Text] [Related]
14. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
15. An immunogenic personal neoantigen vaccine for patients with melanoma.
Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
[TBL] [Abstract][Full Text] [Related]
16. Self-recognition and tumor response to immunotherapy.
Ernstoff MS
J Clin Oncol; 2005 Sep; 23(25):5875-7. PubMed ID: 16087939
[No Abstract] [Full Text] [Related]
17. Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy.
Finnigan JP; Rubinsteyn A; Hammerbacher J; Bhardwaj N
Oncology (Williston Park); 2015 Dec; 29(12):970-2, 974-5. PubMed ID: 26676902
[No Abstract] [Full Text] [Related]
18. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
19. Personalized cancer neoantigen vaccines come of age.
Chu Y; Liu Q; Wei J; Liu B
Theranostics; 2018; 8(15):4238-4246. PubMed ID: 30128050
[TBL] [Abstract][Full Text] [Related]
20. Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma.
Grabbe S; Haas H; Diken M; Kranz LM; Langguth P; Sahin U
Nanomedicine (Lond); 2016 Oct; 11(20):2723-2734. PubMed ID: 27700619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
